A5002280687- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Pregnancy and Medication Impact
- Liver Disease and Transplantation
- Transplantation: Methods and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Pharmaceutical Economics and Policy
- Neurological Complications and Syndromes
- Organ and Tissue Transplantation Research
Regione del Veneto
2022-2024
The goal of post-transplant immunosuppressive drug therapy is to prevent organ rejection while minimizing toxicities. In clinical practice, a multidrug approach commonly used and involves drugs with different mechanisms action, including calcineurin inhibitors (CNI) (tacrolimus or cyclosporine), antimetabolite (antimet) (mycophenolate azathioprine), mechanistic target rapamycin (mTOR) (sirolimus everolimus), and/or steroids. Although evidence based on several randomized trials available, the...
Maintenance immunosuppressive therapy used in kidney transplantation typically involves calcineurin inhibitors, such as tacrolimus or cyclosporine, combination with mycophenolate mechanistic target of rapamycin (mTORi) without corticosteroids. An Italian retrospective multicentre observational study was conducted to investigate the risk-benefit profile different regimens. We identified all subjects who underwent transplant between 2009 and 2019, using healthcare claims data. Patients on...
Background In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors ( CNI: tacrolimus-TAC or cyclosporine-CsA ), antimetabolites antiMs mammalian target of rapamycin mTORis and corticosteroids. However, data on immunosuppressive therapy by organ its space–time variability lacking. Methods An Italian multicentre observational cohort study was conducted using health information systems. Patients with incident transplant during...
Very scanty evidence is available on factors influencing the choice of immunosuppressive drug therapy after kidney transplantation.
This study evaluates the use, benefit-risk profile, and economic impact of generic immunosuppressants (tacrolimus-TAC, cyclosporine-CsA, mycophenolate-MYC) in kidney liver transplant recipients compared to brand-name drugs.
Objectives To investigate the use of maintenance immunosuppressive treatments following liver transplantation and to compare their risk–benefit profiles in clinical practice. Design Retrospective multicentrer cohort study. Setting Four Italian regions (Lombardy, Veneto, Lazio, Sardinia). Methods Data were integrated from national transplant information system administrative claims data four regions. All adults who underwent incident between 2009 2019 identified categorised into two groups:...
Abstract Background Very scanty evidence is available on factors influencing the choice of immunosuppressive drug therapy after kidney transplantation. Methods. An Italian multiregional real-world study was conducted integrating national transplant information system and claims data. All patients undergoing transplantation for first time during 2009–2019 (incident patients) were considered. Multilevel logistic models used to estimate Odds Ratio (OR) corresponding 95% Confidence intervals....
<title>Abstract</title> <bold>Introduction</bold> Post-liver transplantation immunosuppressive therapy typically involves the combination of various drugs: calcineurin inhibitors (tacrolimus-TAC or cyclosporine-CsA), with potential addition mycophenolate-MMF mTOR with/without corticosteroids. This study aimed to investigate use treatments and compare their risk-benefit profiles in clinical practice. <bold>Methods</bold> retrospective multicenter cohort integrated data from national...